{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endocrine+Disorders+of+Female+Reproductive+System&page=39",
    "query": {
      "condition": "Endocrine Disorders of Female Reproductive System",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 2050,
    "total_pages": 205,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endocrine+Disorders+of+Female+Reproductive+System&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endocrine+Disorders+of+Female+Reproductive+System&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T22:29:55.595Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05199272",
      "title": "A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Clear Cell Renal Cell Carcinoma",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "Neuroendocrine Tumors",
        "MSI-H Cancer",
        "Cancer With A High Tumor Mutational Burden",
        "Extensive-stage Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "23ME-00610",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "23andMe, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 141,
      "start_date": "2021-12-29",
      "completion_date": "2025-03",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-11-22T22:29:55.595Z",
      "location_count": 10,
      "location_summary": "Palo Alto, California • Atlanta, Georgia • Detroit, Michigan + 7 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05199272"
    },
    {
      "nct_id": "NCT07282158",
      "title": "Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovarian Carcinoma",
        "Psychiatric Disorder"
      ],
      "interventions": [
        {
          "name": "Behavioral Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Interview",
          "type": "OTHER"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2026-02-24",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-11-22T22:29:55.595Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07282158"
    },
    {
      "nct_id": "NCT05617755",
      "title": "AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Ovarian Epithelial",
        "Ovarian Neoplasms",
        "Fallopian Tube Neoplasms",
        "Peritoneal Neoplasms",
        "Neoplasms, Glandular and Epithelial",
        "Ovarian Diseases",
        "Genital Neoplasm, Female",
        "Abdominal Neoplasm",
        "Recurrence"
      ],
      "interventions": [
        {
          "name": "AB-1015",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Arsenal Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2022-11-29",
      "completion_date": "2026-10-26",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-22T22:29:55.595Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Aurora, Colorado • Iowa City, Iowa + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05617755"
    },
    {
      "nct_id": "NCT04644315",
      "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Colorectal Neoplasms",
        "Melanoma",
        "Pancreatic Neoplasms",
        "Sarcoma",
        "Ovarian Neoplasms",
        "Brain Neoplasms",
        "Thyroid Neoplasms",
        "Neuroendocrine Tumors",
        "Cholangiocarcinoma",
        "Salivary Gland Neoplasms",
        "Head and Neck Neoplasms",
        "Thyroid Cancer, Papillary",
        "Lymphoma, Large-Cell, Anaplastic",
        "Neoplasms by Site",
        "Respiratory Tract Neoplasms",
        "Thoracic Neoplasms",
        "Respiratory Tract Diseases",
        "Carcinoma, Bronchogenic",
        "Bronchial Neoplasms",
        "Intestinal Neoplasms",
        "Gastrointestinal Neoplasms",
        "Digestive System Neoplasms",
        "Digestive System Diseases",
        "Gastrointestinal Diseases",
        "Colonic Diseases",
        "Intestinal Diseases",
        "Central Nervous System"
      ],
      "interventions": [
        {
          "name": "Alectinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-05-24",
      "completion_date": "2022-05-16",
      "has_results": true,
      "last_update_posted_date": "2023-08-07",
      "last_synced_at": "2026-11-22T22:29:55.595Z",
      "location_count": 29,
      "location_summary": "Culver City, California • Los Angeles, California • Sacramento, California + 21 more",
      "locations": [
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04644315"
    },
    {
      "nct_id": "NCT07564141",
      "title": "Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Platinum-Sensitive Ovarian Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Rina-S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "PLD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 688,
      "start_date": "2026-08-28",
      "completion_date": "2031-11",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-22T22:29:55.595Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Danbury, Connecticut • Tigard, Oregon + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Tigard",
          "state": "Oregon"
        },
        {
          "city": "Bensalem",
          "state": "Pennsylvania"
        },
        {
          "city": "South Jordan",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07564141"
    },
    {
      "nct_id": "NCT06040970",
      "title": "Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Malignant Neoplasm of Uterus"
      ],
      "interventions": [
        {
          "name": "Sacituzumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 54,
      "start_date": "2024-10-28",
      "completion_date": "2032-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-11-22T22:29:55.595Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06040970"
    },
    {
      "nct_id": "NCT06545942",
      "title": "Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Prostate Cancer",
        "Pancreas Cancer",
        "Breast Cancer",
        "Ovarian Cancer",
        "Homologous Recombination Deficiency"
      ],
      "interventions": [
        {
          "name": "MOMA-313",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MOMA Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2024-08-13",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-11-22T22:29:55.595Z",
      "location_count": 12,
      "location_summary": "Goodyear, Arizona • La Jolla, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06545942"
    },
    {
      "nct_id": "NCT05500508",
      "title": "Oral AMXT 1501 Dicaprate in Combination With IV DFMO",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumor",
        "Solid Carcinoma",
        "Advanced Cancer",
        "DIPG Brain Tumor",
        "Ovary Cancer",
        "Breast Cancer",
        "Papillary Thyroid Cancer",
        "Head and Neck Cancer",
        "Gastric Cancer",
        "Nsclc",
        "Mesotheliomas Pleural",
        "Mesothelioma Peritoneum",
        "Esophageal Cancer",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Endometrial Cancer",
        "Cervical Cancer",
        "Melanoma",
        "Colorectal Cancer",
        "Glioma, Malignant"
      ],
      "interventions": [
        {
          "name": "AMXT1501",
          "type": "DRUG"
        },
        {
          "name": "DFMO",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aminex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2022-11-29",
      "completion_date": "2024-12-12",
      "has_results": false,
      "last_update_posted_date": "2024-12-24",
      "last_synced_at": "2026-11-22T22:29:55.595Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05500508"
    },
    {
      "nct_id": "NCT00769613",
      "title": "Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "cytomegalovirus IE-1-specific cytotoxic T lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cytomegalovirus pp65-specific cytotoxic T lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunological diagnostic method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2008-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-11-22T22:29:55.595Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00769613"
    },
    {
      "nct_id": "NCT00069160",
      "title": "Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Neoplasms",
        "Ovarian Neoplasms",
        "Cervix Neoplasms",
        "Renal Neoplasms"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "tariquidar",
          "type": "DRUG"
        },
        {
          "name": "99mTc-sestamibi imaging",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2003-09",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2012-10-12",
      "last_synced_at": "2026-11-22T22:29:55.595Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00069160"
    }
  ]
}